金宇生物技术股份有限公司：关于股东股份质押的详细公告
一、公告重点信息
- 股东质押概况： 内蒙古金宇生物控股有限公司（简称“生物控股”）将其持有的2,450,000股金宇生物技术股份有限公司（简称“金宇生物”）无限售流通股质押给浙商证券股份有限公司，相关手续已在2026年5月11日办理完成。
- 本次质押后累计数据： 生物控股累计质押金宇生物股份18,270,000股，占其持有金宇生物股份总数的14.56%，占公司总股本的1.64%。
- 质押用途： 质押融资资金用于融资周转。
- 质押期限： 本次质押起始日为2026年5月11日，到期日为2027年5月11日。
- 不存在重大资产重组业绩补偿担保或其他保障用途： 本次质押股份未被用作重大资产重组业绩补偿等事项的担保或其他保障用途。
二、详细数据与影响分析
- 生物控股及一致行动人持股及质押情况：
- 生物控股持有公司股份：125,510,800股，占公司总股本11.29%。
- 本次质押前，累计质押股份15,820,000股；本次质押后累计18,270,000股。
- 质押股份占其持股14.56%，占公司总股本1.64%。
- 其他一致行动人（张翀宇、张竞）均无质押。
- 对公司控制权和经营影响： 公告明确指出，本次质押不会导致公司实际控制权发生变更，也不会对公司生产经营和公司治理产生影响。
- 风险提示及应对措施： 若后续出现平仓风险，生物控股及一致行动人将采取补充质押或追加保证金等措施应对风险，确保不会对公司造成重大不利影响。
- 后续信息披露义务： 若质押事项出现其他重大变动，公司将依法及时披露相关信息，保障投资者知情权。
三、投资者需关注的重要事项及潜在影响
- 股份质押比例： 生物控股累计质押股份达14.56%，但目前质押比例较低，不会对控股权及公司稳定性造成实质性影响。
- 资金用途与流动性： 质押融资资金主要用于周转，未涉及重大资产重组、业绩补偿等高风险用途，说明控股股东财务状况总体健康。
- 可能影响股价因素： 若后续质押比例进一步提升或出现补充质押、平仓风险，可能引发市场关注并对公司股价产生波动。
- 公司承诺： 公司及控股股东承诺，若出现质押相关重大变动，将依法及时披露，保障市场透明度。
四、结论
本次股东股份质押公告显示，生物控股适度通过股份质押进行融资，当前质押比例对公司控制权及经营无重大影响，但投资者仍应持续关注后续质押比例变化及可能产生的相关风险。公告的及时披露有助于维护公司信息透明度和投资者权益。
免责声明： 本文仅作为公开信息解读，不构成任何投资建议。投资者据此操作，风险自负。
English Translation
Jinyu Bio-Technology Co., Ltd.: Detailed Announcement on Shareholder Share Pledge
1. Key Points of the Announcement
- Overview of Share Pledge: Inner Mongolia Jinyu Bio Holdings Co., Ltd. (“Bio Holdings”) pledged 2,450,000 unrestricted tradable shares of Jinyu Bio-Technology Co., Ltd. (“Jinyu Bio”) to Zheshang Securities Co., Ltd., with the related procedures completed on May 11, 2026.
- Cumulative Data After This Pledge: After this transaction, the total pledged shares by Bio Holdings reach 18,270,000, accounting for 14.56% of its holdings and 1.64% of the company’s total share capital.
- Pledge Purpose: The funds raised from the pledge are intended for financing turnover.
- Pledge Period: The pledge starts on May 11, 2026, and is due on May 11, 2027.
- No Major Asset Restructuring Guarantee: The pledged shares are not used as a guarantee for major asset restructuring performance compensation or other security purposes.
2. Detailed Data and Impact Analysis
- Holdings and Pledge Status of Bio Holdings and Acting-In-Concert Parties:
- Bio Holdings holds 125,510,800 shares, accounting for 11.29% of the company’s total share capital.
- Before this pledge, cumulative pledged shares were 15,820,000; after, 18,270,000.
- Pledged shares account for 14.56% of its holdings and 1.64% of total share capital.
- Other acting-in-concert parties (Zhang Chongyu, Zhang Jing) have no pledges.
- Impact on Company Control and Operations: The announcement states this pledge will not lead to changes in actual control or affect company operations and governance.
- Risk Warning and Response: If margin call risk arises, Bio Holdings and acting-in-concert parties will take measures such as additional pledges or collateral to manage risk.
- Subsequent Disclosure Obligations: If there are significant changes related to the pledge, the company will disclose information in a timely manner as required by law.
3. Key Issues and Potential Impact for Investors
- Pledge Ratio: Bio Holdings’ cumulative pledge ratio is 14.56%, currently posing low risk to company control or stability.
- Use of Funds and Liquidity: The pledged funds are for turnover, not for high-risk uses such as major asset restructuring or performance compensation, indicating healthy financial status.
- Potential Price-Sensitive Factors: If the pledge ratio significantly increases or margin call risk arises, it could attract market attention and cause share price volatility.
- Company Commitment: The company and controlling shareholder commit to timely disclosure of any major changes related to the pledge, ensuring market transparency.
4. Conclusion
This share pledge announcement shows Bio Holdings is moderately using share pledges for financing, with the current ratio unlikely to affect control or company operations. Investors should monitor future changes in the pledge ratio and related risks. Timely information disclosure helps maintain transparency and protect investor interests.
Disclaimer: This article is for information interpretation only and does not constitute investment advice. Investors act at their own risk.
